Reich Adi, Bae Alison S, Barnes Aileen M, Cabral Wayne A, Hinek Aleksander, Stimec Jennifer, Hill Suvimol C, Chitayat David, Marini Joan C
Bone and Extracellular Matrix Branch (A.R., A.S.B., A.M.B., W.A.C., J.C.M.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, and Department of Diagnostic Radiology (S.C.H.), National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, Maryland 20892; Physiology and Experimental Medicine Program (A.H.), Heart Center, Hospital for Sick Children, University of Toronto, Ontario, Canada M5S 3OA4; Division of Diagnostic Imaging (J.S.), Department of Pediatrics, and Division of Clinical and Metabolic Genetics (D.C.), Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada M5G 1X8; and The Prenatal Diagnosis and Medical Genetics Program (D.C.), Department of Obstetrics and Gynecology, Mt Sinai Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1Z5.
J Clin Endocrinol Metab. 2015 Feb;100(2):E325-32. doi: 10.1210/jc.2014-3082. Epub 2014 Nov 11.
Patients with type V osteogenesis imperfecta (OI) are heterozygous for a dominant IFITM5 c.-14C>T mutation, which adds five residues to the N terminus of bone-restricted interferon-induced transmembrane-like protein (BRIL), a transmembrane protein expressed in osteoblasts. Type V OI skeletal findings include hyperplastic callus formation, ossification of the forearm interosseous membrane, and dense metaphyseal bands.
The objective of this study was to examine the role of osteoblasts in the active mineralization traits of type V OI and the effect of the IFITM5 mutation on type I collagen.
We identified eight patients with the IFITM5 c.-14C>T mutation. Cultured osteoblasts from type V OI patients were used to study osteoblast differentiation and mineralization.
We verified the expression and stability of mutant IFITM5 transcripts. In differentiated type V OI primary osteoblasts in culture, the IFITM5 expression and BRIL level is comparable with control. Both early and late markers of osteoblast differentiation are increased in type V OI osteoblasts. Mineralization, assayed by alizarin red staining, was increased in type V OI osteoblasts compared with control. However, type V OI osteoblasts have significantly decreased COL1A1 transcripts in mid- to late differentiation. Type I collagen protein is concomitantly decreased, with decreased cross-linked collagen in matrix and altered appearance of fibrils deposited in culture.
This study demonstrates that type V OI mineralization has a gain-of-function mechanism at the osteoblast level, which likely underlies the overactive tissue mineralization seen in patients. Decreased type I collagen expression, secretion, and matrix incorporation establish type V OI as a collagen-related defect.
V型成骨不全(OI)患者为显性IFITM5基因c.-14C>T突变的杂合子,该突变使骨限制性干扰素诱导跨膜样蛋白(BRIL)的N端增加了五个氨基酸残基,BRIL是一种在成骨细胞中表达的跨膜蛋白。V型OI的骨骼表现包括骨痂形成增生、前臂骨间膜骨化和干骺端致密带。
本研究旨在探讨成骨细胞在V型OI活跃矿化特征中的作用以及IFITM5突变对I型胶原的影响。
我们鉴定了8例携带IFITM5基因c.-14C>T突变的患者。使用V型OI患者培养的成骨细胞来研究成骨细胞分化和矿化。
我们验证了突变型IFITM5转录本的表达和稳定性。在培养的分化V型OI原代成骨细胞中,IFITM5表达和BRIL水平与对照相当。V型OI成骨细胞中,成骨细胞分化的早期和晚期标志物均增加。与对照相比,通过茜素红染色检测,V型OI成骨细胞的矿化增加。然而,V型OI成骨细胞在分化中期至晚期COL1A水平显著降低。I型胶原蛋白随之减少,基质中交联胶原蛋白减少,培养中沉积的纤维外观改变。
本研究表明,V型OI矿化在成骨细胞水平具有功能获得机制,这可能是患者组织矿化过度活跃的基础。I型胶原表达、分泌和基质整合减少使V型OI成为一种与胶原相关的缺陷。